{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-050346","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.733778+00:00","generated_at":"2026-05-29T02:22:44.358882+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA grants Fast Track Designation to Lipocine for LPCN 1148 in decompensated cirrhosis sarcopenia","bullets":["FDA Fast Track Designation granted to LPCN 1148 for sarcopenia in decompensated cirrhosis, an unmet medical need.","LPCN 1148 is an oral prodrug of bioidentical testosterone; POC Phase 2 study showed improved sarcopenia and clinical outcomes.","Fast Track benefits include more frequent FDA meetings, eligibility for Accelerated Approval, Priority Review, and Rolling Review.","Over 382,000 U.S. patients with decompensated cirrhosis; no FDA-approved treatments for associated sarcopenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-050346","json":"https://secwatch.observer/filing/0001493152-24-050346.json","markdown":"https://secwatch.observer/filing/0001493152-24-050346.md","text":"https://secwatch.observer/filing/0001493152-24-050346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224050346/0001493152-24-050346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224050346/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:22:44.358882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}